Collegium Pharmaceutical, Inc.
$24.72-$0.49 (-1.9%)
Last close · Data as of Nov 20, 2026
- Market cap
- $1.1B
- P/E
- 16.9x
- EV / EBITDA
- 4.1x
- Revenue
- $780.6M
- Net margin
- 8.1%
- ROCE
- 14.7%
Price chart
Technical chartScreen technicals →-43.8% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +6.4%
- 3M
- -10.2%
- 6M
- -27.8%
- 1Y
- -43.8%
- 5Y
- +31.1%
52-week range
Day change -$0.49 (-1.9%) from $25 to $25 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in COLL, bought on each weekday since 2021.
News & filings
What Collegium Pharmaceutical filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthEV / EBITDA of 4.1 against a peer median of 15.7.
Concerns (1)
- The P/E of 16.9 is 56% above the peer median of 10.8.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
Read moreShow less
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
- Sector
- Healthcare
- Shares outstanding
- 31.8M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $1.1B
- P/E
- 16.9x
- P/B
- 3.5x
- EV / EBITDA
- 4.1x
- EV / Sales
- 2.1x
- P/S
- 1.4x
- 52-week high
- $49.84
- 52-week low
- $21.53
Profitability
- Operating margin
- 22.9%
- Net margin
- 8.1%
- EBITDA margin
- 51.4%
- ROE
- 20.8%
- ROCE
- 14.7%
- ROA
- 3.8%
- Asset turnover
- 0.47
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $780.6M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 23.6%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 18.9%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -9.1%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $327.6M
Solvency
- Current ratio
- 1.57
- Debt / Equity
- 2.70
- Debt / Assets
- 0.49
- CFO / Net profit
- 5.24
- Cash / Market cap
- 21.8%
Where the revenue went
Of every $100 of FY2025 revenue, $8 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $317.3M |
| Revenue | Gross profit | $463.3M |
| Gross profit | Selling, general and administrative | $284.8M |
| Gross profit | Other operating expenses | $10.0k |
| Gross profit | Operating income | $178.4M |
| Operating income | Pretax income | $92.6M |
| Operating income | Interest and other expense | $85.8M |
| Pretax income | Tax and other | $29.8M |
| Pretax income | Net income | $62.9M |
Revenue and net profit
Revenue grew 23.6% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $463.9M | -$25.0M |
| FY2023 | $566.8M | $48.2M |
| FY2024 | $631.4M | $69.2M |
| FY2025 | $780.6M | $62.9M |
Cash flows
FY2025: $329.3M from operations, $327.6M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $124.2M | $122.6M |
| FY2023 | $274.7M | $274.3M |
| FY2024 | $205.0M | $203.3M |
| FY2025 | $329.3M | $327.6M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $780.6M+23.6%1Y
- EBITDA
- $401.0M+17.4%1Y
- Net profit
- $62.9M-9.1%1Y
- Cash from operations
- $329.3M+60.7%1Y
- Free cash flow
- $327.6M+61.1%1Y
- Revenue CAGR, 3Y
- 18.9%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $780.6M | $401.0M | $62.9M | $327.6M | 20.8% | +23.6% | -9.1% |
Monthly returns
Month-by-month returns of COLL across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $1.7B |
| Current assets | $691.4M |
| Non-current assets | $965.4M |
| Liabilities | $1.4B |
| Current liabilities | $440.0M |
| Non-current liabilities | $915.1M |
| Equity | $301.7M |
| Paid-in capital | $625.0M |
| Retained earnings | -$101.1M |
| Treasury stock | $222.5M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; COLL highlighted.
P/E against peers
COLL trades at 16.9x earnings against a peer median of 10.8x (a 56% premium).
Not shown (no positive earnings and no EV / Sales): Savara Inc., Omada Health, Inc., Azenta, Inc., QuidelOrtho Corporation.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Collegium Pharmaceutical, Inc.COLLthis companyP/E ↑ premium | $1.1B | 16.9x | 3.5x | 20.8% | 4.1x |
| MannKind CorporationMNKD | $1.1B | 185.5x | -21.3x | -11.5% | 26.8x |
| Savara Inc.SVRA | $1.1B | -9.1x | 5.3x | -58.5% | -8.8x |
| Omada Health, Inc.OMDA | $1.1B | -84.7x | 4.7x | -5.6% | -181.0x |
| Xeris Biopharma Holdings, Inc.XERS | $1.1B | 1916.5x | 77.6x | 4.0% | 28.6x |
| CONMED CorporationCNMD | $1.1B | 22.5x | 1.0x | 4.6% | 10.5x |
| Azenta, Inc.AZTA | $1.1B | -18.9x | 0.6x | -3.2% | 20.8x |
| The Pennant Group, Inc.PNTG | $1.0B | 35.4x | 3.1x | 8.9% | 24.4x |
| QuidelOrtho CorporationQDEL | $1.0B | -0.9x | 0.5x | -58.9% | -7.7x |
| Peer median | — | 10.8x | 2.1x | -4.4% | 15.7x |
Year-to-date ROI
COLL since 1 January, against earlier years.
Historical volatility
COLL's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 7.2% |
| FY2023 | 29.5% |
| FY2024 | 26.4% |
| FY2025 | 22.9% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $780.6M |
| Cost of revenueCost Of Revenue | $317.3M |
| Gross profitGross Profit | $463.3M |
| Operating expensesOperating Expense | $284.8M |
| Research and developmentResearch And Development | — |
| Selling, general and administrativeSelling General And Administration | $284.8M |
| Total expensesTotal Expenses | $602.1M |
| Operating incomeOperating Income | $178.4M |
| Interest and other | |
| Pretax incomePretax Income | $92.6M |
| TaxTax Provision | $29.8M |
| Net incomeNet Income | $62.9M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $1.7B |
| Current assetsCurrent Assets | $691.4M |
| Non-current assetsTotal Non Current Assets | $965.4M |
| LiabilitiesTotal Liabilities Net Minority Interest | $1.4B |
| Current liabilitiesCurrent Liabilities | $440.0M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $915.1M |
| EquityTotal Equity Gross Minority Interest | $301.7M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $329.3M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $329.3M |
| Net income, continuing operationsNet Income From Continuing Operations | $62.9M |
| Depreciation and amortisationDepreciation And Amortization | $226.1M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $226.1M |
| Depreciation | $4.2M |
| Amortization cash flowAmortization Cash Flow | $221.9M |
| Amortization of intangiblesAmortization Of Intangibles | $221.9M |
| Amortization of securitiesAmortization Of Securities | -$1.1M |
| Stock-based compensationStock Based Compensation | $41.9M |
| Deferred taxDeferred Tax | -$25.7M |
| Deferred income taxDeferred Income Tax | -$25.7M |
| Operating gains and lossesOperating Gains Losses | $16.0M |
| Change in working capitalChange In Working Capital | $3.8M |
| Other non-cash itemsOther Non Cash Items | $5.5M |
| Investing cash flowInvesting Cash Flow | -$63.5M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$63.5M |
| Capital expenditureCapital Expenditure | -$1.7M |
| Purchase of PP&EPurchase Of PPE | -$1.7M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$1.7M |
| AcquisitionsPurchase Of Business | $0.00 |
| Net acquisitions and disposalsNet Business Purchase And Sale | $0.00 |
| Purchase of investmentsPurchase Of Investment | -$127.0M |
| Sale of investmentsSale Of Investment | $65.2M |
| Net investment purchases and salesNet Investment Purchase And Sale | -$61.8M |
| Purchase of intangiblesPurchase Of Intangibles | — |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | — |
| Financing cash flowFinancing Cash Flow | -$110.2M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$110.2M |
| Debt issuedIssuance Of Debt | $565.2M |
| Debt repaidRepayment Of Debt | -$635.6M |
| Net debt issuedNet Issuance Payments Of Debt | -$70.4M |
| Long-term debt issuedLong Term Debt Issuance | $565.2M |
| Long-term debt repaidLong Term Debt Payments | -$635.6M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$70.4M |
| Net common stock issuedNet Common Stock Issuance | -$25.1M |
| Common stock repurchasedCommon Stock Payments | -$25.1M |
| Share buybacksRepurchase Of Capital Stock | -$25.1M |
| Stock options exercisedProceeds From Stock Option Exercised | $5.6M |
| Other financing chargesNet Other Financing Charges | -$20.4M |
| Change in cashChanges In Cash | $155.6M |
| Cash at the start of the yearBeginning Cash Position | $96.6M |
| Cash at the end of the yearEnd Cash Position | $252.2M |
| Free cash flowFree Cash Flow | $327.6M |
| Supplemental |
Learn while you research
Academy chapters picked for Collegium Pharmaceutical, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Growth Investing24% revenue growth is in the top tier, learn how to value growth.7 min read
- 03 Leverage RatiosDebt/Equity of 2.70 is elevated, understand what that means for solvency.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read